Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies

Abstract Introduction Standard therapy for patients with mild to moderate atopic dermatitis (AD) typically includes topical therapies; however, patients with more extensive AD and/or AD refractory to topical therapy may benefit from systemic treatment. Ruxolitinib cream monotherapy has demonstrated...

Полное описание

Библиографические подробности

Главные авторы:	Eric L. Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F. Eichenfield
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Adis, Springer Healthcare 2024-07-01
Серии:	Dermatology and Therapy
Предметы:	Atopic dermatitis Ruxolitinib cream Janus kinase inhibition JAK
Online-ссылка:	https://doi.org/10.1007/s13555-024-01219-8
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!